Takeda Pharmaceutical Co (Takeda), a Japanese multinational pharmaceutical and biopharmaceutical company, has said it would import and distribute 50 million doses of Moderna Inc's COVID-19 vaccine candidate in Japan, Reuter news agency reported on Thursday.
Under this deal, Takeda will be responsible for securing regulatory approval for the vaccine, known as mRNA-1273, with supply starting in the first half of 2021, Takeda said in a release.
Reportedly, the companies were previously in talks to supply 40 million or more doses of the vaccine in Japan.
Moderna's candidate is in late-stage trials in the US.
Also, Takeda has agreed to produce Novavax Inc's COVID-19 vaccine, aiming to make 250 million doses for use in Japan.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses